- Conditions
- Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
- Interventions
- MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
- Drug
- Lead sponsor
- South Plains Oncology Consortium
- Network
- Eligibility
- 12 Months to 20 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 6
- States / cities
- Cincinnati, Ohio • Oklahoma City, Oklahoma • Dallas, Texas + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Neuroblastoma, Neuroblastoma
- Interventions
- Fenretinide/LXS Oral Powder, Ketoconazole, Vincristine
- Drug
- Lead sponsor
- South Plains Oncology Consortium
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Dallas, Texas • Fort Worth, Texas + 1 more
- Conditions
- Cancer of Pancreas
- Interventions
- Nintedanib
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Ovarian Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasms, Primary Peritoneal Carcinoma
- Interventions
- Fenretinide/LXS + Ketoconazole
- Drug
- Lead sponsor
- South Plains Oncology Consortium
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 3
- States / cities
- Oklahoma City, Oklahoma • Dallas, Texas • Lubbock, Texas
- Conditions
- Solid Tumor
- Interventions
- Fenretinide (4-HPR) plus Intravenous Safingol
- Drug
- Lead sponsor
- South Plains Oncology Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 3
- States / cities
- Dallas, Texas • Lubbock, Texas
- Conditions
- Recurrent Neuroblastoma, Neuroblastoma
- Interventions
- Fenretinide Lym-X-Sorb Oral Powder, Ketoconazole
- Drug
- Lead sponsor
- South Plains Oncology Consortium
- Network
- Eligibility
- Not listed
- U.S. locations
- 3
- States / cities
- Oklahoma City, Oklahoma • Dallas, Texas • Fort Worth, Texas
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
- Interventions
- Fenretinide, Cytarabine, Methotrexate
- Drug
- Lead sponsor
- South Plains Oncology Consortium
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma • Houston, Texas